CIK 0001559053
- Accelerated filer
PROTHENA CORP PUBLIC LTD CO
Sign in to watch- Ticker
- PRTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Ireland
- Entity type
- Operating
- Phone
- +353 12362500
- Business address
- 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, GRAND CANAL DOCKLANDS, DUBLIN 2, Ireland, D02 VK60
- Former names
- Prothena Corp plc, Neotope Corp Ltd
- Open-market buys, last 90 days
- $9,848,721
- in 10 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,848,721. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-28 | Swanson Chad J. Chief Development Officer | Option exercise | +51,000 | 85,000 | ||
| 2026-07-28 | Swanson Chad J. Chief Development Officer | Returned to the company | −40,800 | $8.56 | $349K | 44,200 |
| 2026-07-28 | Swanson Chad J. Chief Development Officer | Shares withheld for taxes | −3,467 | $8.56 | $30K | 40,733 |
| 2026-07-28 | Swanson Chad J. Chief Development Officer | Option exercise · Restricted Stock Units | −51,000 | 0 | ||
| 2026-03-03 | Swanson Chad J. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2025-07-28 | Swanson Chad J. Chief Development Officer | Grant or award | +85,000 | 85,000 | ||
| 2025-03-05 | Swanson Chad J. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +107,500 | 107,500 | ||
| 2024-10-01 | Swanson Chad J. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 |
Page 1 of 1 · 8 trades